Compound News and Research

RSS

St. John's wort not effective for treating ADHD

Children and teens with attention-deficit/hyperactivity disorder (ADHD) who were treated with the herb St. John's wort did not have any greater improvement in ADHD symptoms compared to those who received placebo, according to a study in the June 11 issue of JAMA, the Journal of the American Medical Association.

11 Jun 2008

Compound in red wine could protect the heart from ageing

Researchers in the United States say a natural compound found in red wine may protect the heart against the effects of the ageing process.

4 Jun 2008

ThromboGenics and BioInvent report positive results for anti-PlGF cancer therapeutic TB-403

ThromboGenics NV and co-development partner BioInvent International AB today reported that the results from the first Phase l study of novel anti-cancer agent TB-403 showed that it is safe and well tolerated, with pharmacokinetic properties enabling it to be developed for the treatment of cancer

3 Jun 2008

Chronic inflammation of the intestine or stomach damages DNA

Chronic inflammation of the intestine or stomach can damage DNA, increasing the risk of cancer, MIT scientists have confirmed.

2 Jun 2008

New approach to treating vision loss caused by type 1 Usher syndrome

A new approach to treating vision loss caused by type 1 Usher syndrome (USH1), the most common condition affecting both sight and hearing, will be unveiled by a scientist at the annual conference of the European Society of Human Genetics tomorrow (Tuesday 3 June).

2 Jun 2008

Genta announces initial trial results for novel drug for bone disease

Genta Incorporated has announced the release of final results from the Company's Phase 1 clinical trial of G4544, a proprietary small molecule that is intended as a treatment for diseases associated with accelerated bone loss. Results showed that the drug was very well-tolerated, and that blood levels were achieved in a range that is known to be clinically bioactive. The data were featured in a poster session at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago on Saturday, May 31, 2008.

2 Jun 2008

Acute artificial compound eyes

Insects are a source of inspiration for technological development work. For example, researchers around the world are working on ultra-thin imaging systems based on the insect eye. The principle of hyperacuity has now been successfully incorporated in a technical model.

29 May 2008

Global drug research programme comes to Diamond in Oxfordshire

Diamond has announced that USA-based global biotechnology company Vertex Pharmaceuticals Incorporated is the first industrial user at the UK's world class new research facility, Diamond Light Source

27 May 2008

Avoiding spleen removal for Cooley's anemia sufferers

Researchers from Weill Cornell Medical College may have discovered the precise role of a gene in one of the world's most common blood disorders, beta-thalassemia, commonly known as Cooley's anemia. Along with sickle-cell anemia, Cooley's anemia is the most commonly inherited disease in the world, affecting many people of Mediterranean descent, and 20 out of every 100,000 African-Americans. The World Health Organization estimates that between 50,000-100,000 children are born with the disease each year.

27 May 2008

Bliss Nipple Cream warning from FDA

The U.S. Food and Drug Administration is warning consumers not to use or purchase Mommy's Bliss Nipple Cream, marketed by MOM Enterprises, Inc., because the product contains potentially harmful ingredients that may cause respiratory distress or vomiting and diarrhea in infants.

25 May 2008

Experimental drug blocks prostate cancer in animal study

An experimental drug has blocked the progression of prostate cancer in an animal model with an aggressive form of the disease, new research shows.

22 May 2008

Plant flavonoid luteolin reduces inflammatory response in the brain

Researchers at the University of Illinois report this week that a plant compound found in abundance in celery and green peppers can disrupt a key component of the inflammatory response in the brain. The findings have implications for research on aging and diseases such as Alzheimer's and multiple sclerosis.

20 May 2008

Cancer Research UK and AstraZeneca announce innovative deal for promising anti-cancer compound

Cancer Research UK and Cancer Research Technology (CRT) - the charity's development and commercialisation arm - today announced an innovative new arrangement to progress into clinical development a potential anti-cancer compound from AstraZeneca.

19 May 2008

New dimension discovered in body clock rhythm

Research on what makes the body clock tick has led Dr Michael Hastings of the MRC Laboratory of Molecular Biology in Cambridge to discover a new and unanticipated cog in the human body clock. A patent for the compound involved has been filed by MRC Technology. The results, published in Science, could lead to therapies for people whose sleep is disrupted by shift work or old age.

18 May 2008

A possible cure for pre-eclampsia

A condition which affects one in every ten pregnancies and is responsible for 1,000 baby deaths in Britain each year may have a genetic cause.

13 May 2008

Researchers find link between altered dopamine activity and social anxiety disorder

Using single-photon emission computed tomography (SPECT), researchers in The Netherlands were able to detect biochemical differences in the brains of individuals with generalized social anxiety disorder (also known as social phobia), providing evidence of a long-suspected biological cause for the dysfunction.

12 May 2008

PolyMedix receives clearance to initiate phase I clinical study of novel systemic antibiotic compound

PolyMedix, Inc. has received a notice of no objection from Health Canada for the Company's Clinical Trial Application ("CTA") for its defensin mimetic antibiotic compound, PMX-30063. This notice of no objection allows for the initiation of human clinical studies in Canada. PMX-30063 is the first defensin mimetic antibiotic compound cleared to enter human clinical trials for systemic use, representing an entirely new class of antibiotic drugs.

9 May 2008

Cytopia announces novel anti-cancer drug development collaboration

Cytopia Limited today announced that it has entered into an anti-cancer drug discovery and development collaboration with Cancer Therapeutics CRC Pty Ltd. This agreement leverages Cytopia's early stage drug discovery pipeline of kinase inhibitors, a class of targeted therapeutics that is one of the fastest growing segments of the cancer drug market.

9 May 2008

Nuclear radiation-blocking, anti-chemical, biological-protection fabric granted Australian patent

Ronald DeMeo, MD, MBA, president and chief executive officer with Radiation Shield Technologies (RST), today announced the company has been granted a new Australian patent for Demron, the world's first nuclear radiation-blocking, anti-chemical and biological-protection material.

6 May 2008

Drug candidate to treat smallpox scaled up by new partnership

Two American companies are teaming up for second-round test-phase production of a FDA-designated "fast track" drug candidate to treat smallpox, a deadly virus that is feared to be able to reach people through acts of bio-warfare or bio-terrorism.

5 May 2008